NCT06453018

Brief Summary

Obstructive sleep apnoea (OSA) in children is a prevalent sleep disorder associated with a wide spectrum of morbidities, including neurobehavioural, cardiovascular, and metabolic complications. Positional OSA (POSA) is one of the distinct clinical phenotypes in which obstructive respiratory events occur predominantly while sleeping in the supine position. As the majority of the OSA events in POSA occur in the supine position, positional therapy has become a reasonable non-invasive treatment strategy. The primary objectives of our study are 1) To investigate the feasibility of positional therapy in children with positional OSA; 2) To investigate the efficacy of positional therapy in children with positional OSA. Hypothesis to be tested: 1) Positional therapy is feasible in children with positional OSA. 2\) Positional therapy is efficacious in children with positional OSA by improving sleep related symptoms and quality of life. Design and subjects: A prospective case-control study. 20 children aged 6 to 17 years of age with positional OSA (POSA) will be invited to join the study. Primary and secondary outcome measures: The changes in sleep-related symptoms, quality of life and behavioral measures between the baseline and 3 months after treatment with a positional device therapy. Adherence to the positional device. Statistical Analysis: Continuous data will be presented as mean and standard deviation or median with the interquartile range depending on its distribution, whereas categorical data will be shown as proportions. Changes in outcome measures between the baseline and 3 months after using the positional device will be compared using Wilcoxon signed rank tests. Within-subject differences in the outcome parameters will be tested by paired t-tests, McNemar tests, and marginal homogeneity tests for continuous, dichotomous, and categorical data respectively. Expected results: Positional therapy is practicable and efficacious in children with positional OSA by improving sleep related symptoms.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 1, 2023

Completed
7 months until next milestone

First Posted

Study publicly available on registry

June 11, 2024

Completed
22 days until next milestone

Study Start

First participant enrolled

July 3, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

February 14, 2025

Status Verified

February 1, 2025

Enrollment Period

1.5 years

First QC Date

November 1, 2023

Last Update Submit

February 12, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Sleep related symptoms

    Questionnaire-based assessments on sleep symptoms by Pediatric Sleep Questionnaire (PSQ): The PSQ consists of 22 items, and responses are scored as "yes" = 1, "no" = 0, and "don't know" = missing. The mean response on non-missing items is the score, which can range from 0 to 1. Higher scores on the PSQ indicate a greater likelihood of sleep-related problems. Specifically, a score greater than 0.33 (33% of questions answered positively) suggests a high risk for pediatric sleep-related breathing disorders

    3 months

  • Daytime sleepiness assessment 1

    Questionnaire-based assessments on sleep symptoms by Pediatric Daytime Sleepiness Scale (PDSS): The PDSS consists of 8 questions, each scored on a 5-point Likert scale ranging from 0 to 4. Therefore, the total score can range from 0 to 32. Higher scores on the PDSS indicate greater daytime sleepiness.

    3 months

  • Daytime sleepiness assessment 2

    Questionnaire-based assessments on sleep symptoms by modified Epworth Sleepiness Scale for children and adolescents (ESS-CHAD): The ESS-CHAD consists of 8 questions, each scored on a scale from 0 to 3. Therefore, the total score can range from 0 to 24. Higher scores on the ESS-CHAD indicate greater daytime sleepiness.

    3 months

Secondary Outcomes (3)

  • Quality of life measure

    3 months

  • Behavioural outcomes

    3 months

  • Adherence to intervention

    3 months

Study Arms (1)

Intervention

EXPERIMENTAL

Positional therapy

Device: Positional device, Rematee Bumper Belt or Night Shift

Interventions

Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention

Intervention

Eligibility Criteria

Age6 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age 6-17 years
  • Diagnosis of positional OSA on a baseline diagnostic polysomnography (PSG), defined as 1) an overall OAHI ≥ 5 events/hour (moderate-to-severe OSA), 2) a supine OAHI greater than or equal to two times of the non-supine OAHI, and 3) at least 30 minutes or 10% of total sleep time of supine sleep, and at least 30 minutes or 10% of total sleep time of non-supine sleep observed in the diagnostic PSG (9-11)
  • Informed consent from a parent or a legal guardian

You may not qualify if:

  • Severe OSA with an OAHI ≥ 30 events/hour that conventional treatment such as adenotonsillectomy and CPAP should be considered before positional therapy, severe disease warranting urgent referral for treatment
  • Genetic, syndromal, or metabolic disease
  • Congenital or acquired neuromuscular disease
  • Craniofacial abnormalities
  • Structural or congenital heart disease
  • Severe chronic respiratory disease that may affect the oxygen saturation or ventilation during sleep and positional therapy is regarded as not appropriate
  • Autism spectrum disorder or severe developmental delay (developmental or functional age \<66% of chronological age (16) that could affect the tolerance to the positional device
  • Current treatment with positive airway pressure
  • Skeletal abnormalities or other conditions that restrict the sleeping position

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prince of Wales Hospital

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Kate Ching Ching Chan, MD

    Chinese University of Hong Kong

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kate Ching Ching Chan, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Children aged 6 to 17 years of age with positional OSA (POSA) will receive the positional therapy.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

November 1, 2023

First Posted

June 11, 2024

Study Start

July 3, 2024

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

February 14, 2025

Record last verified: 2025-02

Locations